• 1
    Chaisson RE, Gallant JE, Keruly JC & Moore RD. Impact of opportunistic disease on survival in patients with HIV infection. AIDS 1998; 12:2933.
  • 2
    Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG & Orme IM. Disseminated tuberculosis in interferon-γ gene-disrupted mice. J Exp Med 1993; 178:22437.
  • 3
    Dorman SE & Holland SM. Mutation in the signal-transducing chain of the interferon-γ receptor and susceptibility to mycobacterial infection. J Clin Invest 1998; 101:23649.
  • 4
    Okamura H, Nagata K & Komatsu T et al. A novel costimulatory factor for γ interferon induction found in the livers of mice causes endotoxic shock. Infect Immun 1995; 63:396672.
  • 5
    Okamura H, Tsutsi H & Komatsu T et al. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995; 378:8891.
  • 6
    Lebel-Binay S, Berger A, Zinzindohoue F, Cugnenc P, Thiounn N, Fridman WH & Pages F. Interleukin-18: biological properties and clinical implications. Eur Cytokine Netw 2000; 11:1526.
  • 7
    Kawakami K, Koguchi Y & Qureshi MH et al. Reduced host resistance and Th1 response to Cryptococcus neoformans in interleukin-18 deficient mice. FEMS Microbiol Lett 2000; 186:1216.DOI: 10.1016/s0378-1097(00)00128-2
  • 8
    Ohkusu K, Yoshimoto T & Takeda K et al. Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection. Infect Immun 2000; 68:244956.
  • 9
    Garcia VE, Uyemura K & Sieling PA et al. IL-18 promotes type 1 cytokine production from NK cells and T cells in human intracellular infection. J Immunol 1999; 162:611421.
  • 10
    Wei XQ, Leung BP & Niedbala W et al. Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J Immunol 1999; 163:28218.
  • 11
    Opal SM, Wherry JC & Grint P. Interleukin-10: potential benefits and possible risks in clinical infectious diseases. Clin Infect Dis 1998; 27:1497507.
  • 12
    Bukowski RM. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Semin Oncol 2000; 27:20412.
  • 13
    Qureshi MH, Zhang T, Koguchi Y, Nakashima K, Okamura H, Kurimoto M & Kawakami K. Combined effects of IL-12 and IL-18 on the clinical course and local cytokine production in murine pulmonary infection with Cryptococcus neoformans. Eur J Immunol 1999; 29:6439.DOI: 10.1002/(sici)1521-4141(199902)29:02<643::aid-immu643>;2-e
  • 14
    Hara I, Nagai H & Miyake H et al. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration. Cancer Gene Ther 2000; 7:8390.
  • 15
    Donnelly JJ, Ulmer JB, Shiver JW & Liu MA. DNA vaccines. Annu Rev Immunol 1997; 15:61748.
  • 16
    Cohen AD, Boyer JD & Weiner DB. Modulating the immune response to genetic immunization. FASEB J 1998; 12:161126.
  • 17
    Raz E, Watanabe A & Baird SM et al. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc Natl Acad Sci USA 1993; 90:45237.
  • 18
    Osaki T, Hashimoto W & Gambotto A et al. Potent antitumor effects mediated by local expression of the mature form of the interferon-γ inducing factor, interleukin-18 (IL-18). Gene Ther 1999; 6:80815.
  • 19
    Kim JJ, Trivedi NN & Nottingham LK et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 1998; 28:1089103.DOI: 10.1002/(sici)1521-4141(199803)28:03<1089::aid-immu1089>;2-l
  • 20
    Mor G, Singla M, Steinberg AD, Hoffman SL, Okuda K & Klinman DM. Do DNA vaccines induce autoimmune disease? Human Gene Ther 1997; 8:293300.
  • 21
    Restifo NP & Rosenberg SA. Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr Opin Oncol 1999; 11:507.
  • 22
    Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, Sandstrom E & Wahren B. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998; 351:13205.DOI: 10.1016/s0140-6736(97)09440-3
  • 23
    Wang R, Doolan DL & Le TP et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by malaria DNA vaccines. Science 1998; 282:47680.
  • 24
    Reff ME, Carner K & Chambers KS et al. Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:43545.
  • 25
    Coligan JE, Kruisbeck AM, Margulies DH, Shevach EM & Strober W. Current Protocols in Immunology, London: Wiley Press, 1995.
  • 26
    Bertram MA, Inderlied CB, Yadegar S, Kolanoski P, Yamada JK & Young LS. Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex. J Infect Dis 1986; 154:1945.
  • 27
    Saunders BM, Zhan Y & Cheers C. Endogenous interleukin-12 is involved in resistance of mice to Mycobacterium avium complex infection. Infect Immun 1995; 63:40115.
  • 28
    Kim TS & Cohen EP. Immunization of mice with allogeneic fibroblasts genetically modified for interleukin-2-secretion and expression of melanoma-associated antigens stimulates predetermined classes of antimelanoma effector cells. J Immunother 1994; 16:2435.
  • 29
    Bohn E, Sing A, Zumbihl R, Bielfeldt C, Okamura H, Kurimoto M, Heesemann J & Autenrieth IB. IL-18 (IFN-γ-inducing factor) regulates early cytokine production in, and promotes resolution of, bacterial infection in mice. J Immunol 1998; 160:299307.
  • 30
    Fortier AH, Polsinelli T, Green SJ & Nacy CA. Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, effector cells, and effector molecules. Infect Immun 1992; 60:81725.
  • 31
    Kim TS, DeKruyff RH, Rupper R, Maecker HT, Levy S & Umetsu DT. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J Immunol 1997; 158:413744.
  • 32
    Bermudez LE. Differential mechanisms of intracellular killing of Mycobacterium avium and Listeria monocytogenes by activated human and murine macrophages. The role of nitric oxide. Clin Exp Immunol 1993; 91:27781.
  • 33
    Gomes MS, Florido M, Pais TF & Appelberg R. Improved clearance of Mycobacterium avium upon disruption of the inducible nitric oxide synthase gene. J Immunol 1999; 162:67349.
  • 34
    Doi T, Ando M, Akaike T, Suga M, Sato K & Maeda H. Resistance to nitric oxide in Mycobacterium avium complex and its implication in pathogenesis. Infect Immun 1993; 61:19809.
  • 35
    Jagannath C, Sepulveda A, Actor JK, Luxem F, Emanuele MR & Hunter RL. Effect of poloxamer of CRL-1072 on drug uptake and nitric-oxide-mediated killing of Mycobacterium avium by macrophages. Immunopharmacology 2000; 48:18597.
  • 36
    James SL & Nacy C. Effector functions of activated macrophages against parasites. Curr Opin Immunol 1993; 5:51823.
  • 37
    Bermudez LE. Immunobiology of Mycobacterium avium infection. Eur J Clin Microbiol Infect Dis 1994; 13:10006.
  • 38
    James SL. Role of nitric oxide in parasitic infections. Microbiol Rev 1995; 59:53347.
  • 39
    Gurunathan S, Klinman DM & Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000; 18:92774.
  • 40
    Le TP, Coonan KM & Hedstrom RC et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000; 18:1893901.DOI: 10.1016/s0264-410x(99)00407-7
  • 41
    Chun S, Daheshia M, Lee S, Eo SK & Rouse BT. Distribution fate and mechanism of immune modulation following muscosal delivery of plasmid DNA encoding IL-10. J Immunol 1999; 163:2393402.
  • 42
    Daheshia M, Kuklin N, Kanangat S, Manickan E & Rouse BT. Suppression of ongoing ocular inflammatory disease by topical administration of plasmid DNA encoding IL-10. J Immunol 1997; 159:194552.
  • 43
    Rogy MA, Auffenberg T, Espat NJ, Philip R, Remick D, Wollenberg GK, Copeland EM 3rd & Moldawer LL. Human tumor necrosis factor receptor (p65) and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuates local inflammatory responses. J Exp Med 1995; 181:228993.
  • 44
    Ramsay AJ, Kent SJ, Strugnell RA, Suhrbier A, Thomson SA & Ramshaw IA. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunol Rev 1999; 171:2744.
  • 45
    Conry RM, LoBuglio AF, Loechel F, Moore SE, Sumerel LA, Barlow DL & Curiel DT. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther 1996; 2:5965.
  • 46
    Raz E, Tighe H & Sata Y et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996; 93:51415.DOI: 10.1073/pnas.93.10.5141
  • 47
    Waisman A, Ruiz PJ & Hirschberg DL et al. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat Med 1996; 2:899905.
  • 48
    Dinarello CA. Interleukin-1β, interleukin-18, and the interleukin-1β converting enzyme. Ann N Y Acad Sci 1998; 856:111.